Selecta Biosciences (NASDAQ:SELB) posted its quarterly earnings results on Thursday, March 15th. The company reported ($0.88) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.32), Bloomberg Earnings reports. Selecta Biosciences had a negative return on equity of 110.64% and a negative net margin of 31,556.04%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $15.00 million.
NASDAQ SELB traded down $0.32 during trading hours on Friday, reaching $10.20. 120,454 shares of the stock traded hands, compared to its average volume of 306,418. Selecta Biosciences has a 1 year low of $7.95 and a 1 year high of $24.02. The company has a debt-to-equity ratio of 0.41, a quick ratio of 9.00 and a current ratio of 9.00.
A number of equities research analysts recently issued reports on the company. BidaskClub upgraded Selecta Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 15th. Canaccord Genuity reiterated a “buy” rating on shares of Selecta Biosciences in a research report on Wednesday, January 3rd. Zacks Investment Research downgraded Selecta Biosciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, March 21st. ValuEngine downgraded Selecta Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Mizuho assumed coverage on Selecta Biosciences in a research report on Monday, February 26th. They issued a “buy” rating and a $30.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $23.33.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nationwide Fund Advisors raised its position in Selecta Biosciences by 224.5% during the second quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock valued at $131,000 after purchasing an additional 4,561 shares in the last quarter. Keybank National Association OH purchased a new stake in Selecta Biosciences during the fourth quarter valued at about $143,000. Two Sigma Advisers LP purchased a new stake in Selecta Biosciences during the fourth quarter valued at about $143,000. SG Americas Securities LLC purchased a new stake in Selecta Biosciences during the fourth quarter valued at about $145,000. Finally, The Manufacturers Life Insurance Company raised its position in Selecta Biosciences by 827.0% during the second quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock valued at $224,000 after purchasing an additional 10,040 shares in the last quarter. Institutional investors and hedge funds own 50.16% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Selecta Biosciences (NASDAQ:SELB) Releases Earnings Results, Misses Estimates By $0.32 EPS” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/selecta-biosciences-selb-posts-quarterly-earnings-results.html.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.